Novo Nordisk (NVO) Stock May Be 50% Undervalued Despite Medicare GLP 1 Coverage
Novo Nordisk stock has fallen over the past three years, yet current valuation checks point to a company that still screens as cheap, with both its market multiples and a Discounted Cash Flow (DCF) intrinsic value estimate indicating the shares trade at a discount to assessed worth.
- Novo Nordisk has declined 34.7% over three years, which raises the question of whether recent weakness has already priced in many of the concerns around competition, pricing and growth.
- Medicare coverage of GLP-1 weight loss drugs and ongoing demand for Wegovy may support future cash flows. However, pressure on U.S. pricing, rising competition in obesity treatments and concerns about prescription trends for the oral Wegovy pill remain key risks for how much of that cash flow reaches shareholders.
- The stock earns a high value score, with 5 out of 6 checks suggesting Novo Nordisk trades below what its fundamentals might justify. The DCF intrinsic value estimate currently implies the shares are priced about 49.6% below that assessment.
The issue now is whether Novo Nordisk's current valuation discount fairly compensates investors for the competitive and pricing risks that the recent news flow has highlighted.
Find out why Novo Nordisk's -25.9% return over the last year is lagging behind its peers.
Is Novo Nordisk a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Novo Nordisk is worth today based on the cash it is expected to generate in the future. Novo Nordisk produced trailing twelve month free cash flow of about DKK 48.2b. The model assumes these cash flows continue growing rather than shrinking, and are then discounted back using a 2 Stage Free Cash Flow to Equity approach.
On this basis, the DCF points to an intrinsic value of about $98 per share. This compares with a current share price that implies roughly a 49.6% discount to that estimate. Despite recent concerns around slower prescription trends for the oral Wegovy pill, the market price still sits well below what the cash flow projections suggest for Novo Nordisk.
Taken together, the DCF output indicates that Novo Nordisk stock currently screens as undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 49.6%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.
Is Novo Nordisk a Bargain on Earnings?
The P/E ratio is a useful yardstick for Novo Nordisk because earnings are a key focus for shareholders in a profitable pharmaceuticals business. Novo Nordisk currently trades on a P/E of 11.7x, which is below both the wider pharmaceuticals industry average of 14.9x and a peer group average of 24.5x. On simple comparisons, the stock is priced at a discount to many listed competitors.
A more tailored yardstick suggests Novo Nordisk could justify a P/E of about 23.4x, based on factors such as its profitability profile, scale and sector risks. Against that fair ratio, the current 11.7x multiple implies the market is assigning a sizeable discount to what those characteristics might support. This points to a situation where earnings, as currently valued, do not appear aggressively priced.
On the P/E multiple, Novo Nordisk stock appears undervalued relative to both its sector and a more company specific fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Novo Nordisk Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Novo Nordisk's valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price. Each one treats fair value as a thesis about Novo Nordisk's business that can be tracked over time, so you can see how the underlying assumptions hold up as new information emerges.
One of the top community narratives on Novo Nordisk: 48% undervalued
"Current sentiment has swung deeply negative, but expectations are now low, and the company’s development-stage pipeline beyond Wegovy appears largely unreflected in today’s pricing..."
Read one of the top narratives on Novo Nordisk
Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!
The Bottom Line
For Novo Nordisk, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view point in the same direction, with the stock screening as undervalued on cash flows and on P/E compared with peers and a tailored fair ratio. The broader valuation checks also lean supportive, which puts the focus squarely on whether competitive pressure, U.S. pricing and obesity drug prescription trends limit how much of the forecast cash flow ultimately benefits shareholders. The central question from here is whether those risks justify the current discount or whether the market is underestimating the durability of Novo Nordisk's earnings power.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com